PATENT CLAIM ANALYSIS

Application Number: 15753237
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-09
Patent Classification: ["514", "049000"]

Abstract:
Disclosed is a combination of gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate (chemical name: 2′-Deoxy-2′,2′-difluoro-D-cytidine-5′-O-[phenyl (benzoxy-L-alaninyl)]phosphate) (NUC-1031) and a platinum-based anticancer agent selected from carboplatin, dicycloplatin, oxaliplatin, satraplatin and nedaplatin. The combinations are useful in the treatment of cancer and particularly ovarian cancer.

Claim (Index 28):
The method of  claim 13 , wherein the dose of gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate administered at each administration event is between 250 mg/m 2  and 1250 mg/m 2 .

Metadata:
- Claim Count in Document: 59.0
- Percentile: 88.0
- Lexical Diversity: 1.34884
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15308475', '15308491', '15514673', '15291833', '13032532']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7381084122620367
- 35 USC 102 Novelty (BERT): 0.5357407144477526
- Combined Prediction Score: 0.7178716424806083
- Mean Citation Score: 263.495558
- Max Citation Score: 335.3714
- Similarity Product: 220.8903872656584

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test